Announcement selection

Announcement selection | Sino Biopharm's 'Liraglutide Injection' is approved for listing; HK Telecom-SS plans to sell the equity of a subsidiary for $870 million.

cls.cn · Jun 26 08:18

Important Announcement for Hong Kong Stocks.

1) Company News

$KARRIE INT'L (01050.HK)$Announced performance for the year ended March 31: Revenue of HKD 2.916 billion, a decrease of 5% year-on-year; net income of HKD 170 million, a decrease of 56.1% year-on-year.

$ESPRIT HOLDINGS (00330.HK)$Plans to sell trademark matters along with all ownership and interests arising from or related to such trademarks for a price of approximately USD 47.5 million.

$GCL NEWENERGY (00451.HK)$Subsidiary intends to subscribe for 14,000 A-class shares of Asia-IO Clean Energy Partners SP for USD 14 million.

$FOSUN PHARMA (02196.HK)$Participated in the establishment of the Shenzhen Biomedical Industry Fund, which has been registered with the China Securities Investment Fund Association.

$SINO BIOPHARM (01177.HK)$The developed Liraglutide Injection has been approved for listing and is mainly used to control blood sugar in adult patients with type 2 diabetes.

$MABPHARM-B (02181.HK)$The market registration application for the core product CMAB009 Enrilotumab (Cetuximab Beta Injection) has been approved.

$SIMCERE PHARMA (02096.HK)$Enrilotumab (Cetuximab Beta Injection), which has been approved for marketing in cooperation with Mabpharm Limited, can be used in combination for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer.

$SH PHARMA (02607.HK)$The market launch application for Hydrocortisone API has been approved. IQVIA database shows that the hospital procurement amount of related Hydrocortisone products in 2023 is about RMB 174 million.

$CSPC PHARMA (01093.HK)$The company's first mRNA-LNP-based chimeric antigen receptor (CAR)-T cell injection (SYS6020) has been approved for clinical trials.

$JUNSHI BIO (01877.HK)$New indication of Trastuzumab for first-line treatment of advanced triple-negative breast cancer has been approved for marketing.

$HKT Trust and HKT (06823.HK)$Intends to sell the equity of Regional Link Telecom Services Holdings for USD 870 million.

2) Repurchase Dynamics

$TENCENT (00700.HK)$Repurchased 2.62 million shares for HKD 1.002 billion on June 25th.

$MEITUAN-W (03690.HK)$Repurchased 4.27 million shares for HKD 500 million on June 25th.

$HSBC HOLDINGS (00005.HK)$Repurchased 3.5 million shares for HKD 236 million on June 24th.

$AIA (01299.HK)$On June 25th, the company repurchased 2.855 million shares for HKD 157 million.

$CSPC PHARMA (01093.HK)$On June 25th, the company repurchased 9.35 million shares for HKD 593.887 million.

$PRU (02378.HK)$On June 24th, the company repurchased 0.682 million shares for GBP 5.15 million.

$STANCHART (02888.HK)$On June 24th, the company repurchased 1.0898 million shares for GBP 7.9776 million.

$KUAISHOU-W (01024.HK)$On June 25th, the company repurchased 0.625 million shares for HKD 29.31 million.

$XIAOMI-W (01810.HK)$On June 25th, the company repurchased 1.5 million shares for HKD 26.56 million.

$HANG SENG BANK (00011.HK)$On June 25th, the company repurchased 0.2 million shares for HKD 20.55 million.

$LINKLOGIS-W (09959.HK)$On June 25th, the company repurchased 8 million shares for HKD 16.78 million.

$SWIRE PACIFIC A (00019.HK)$On June 25th, the company repurchased 0.207 million shares for HKD 14.46 million.

$SKYWORTH GROUP (00751.HK)$On June 25th, the company repurchased 3.32 million shares for HKD 10.3093 million.

$ZHONGSHENG HLDG (00881.HK)$On June 25th, the company repurchased 0.824 million shares for HKD 10.214 million.

$KINGSOFT (03888.HK)$On June 25th, the company repurchased 0.4348 million shares for HKD 9.9979 million.

Editor/new

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.